JAK2 and anemia: NS-018 potently decreases viability of cell lines expressing constitutively activated JAK2, suppresses endogenous erythroid colony formation by primary cells from PV patients, reduces leukocytosis and splenomegaly, improves BM fibrosis, and prolongs survival in a mouse model of JAK2 V617F-driven MF without causing peripheral anemia or thrombocytopenia [157].